Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and everolimus in advanced, recurrent, or metastatic squamous cell carcinoma of the head and neck
ISRCTN73814534Phase 2Terminated
- Sponsor
- University College London
- Start
- Aug 2007
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of everolimus and docetaxel in head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by University College London. Primary endpoints: Safety and tolerability of docetaxel plus everolimus, Maximum tolerated dose of everolimus in combination and 1 more. Started Aug 2007; status: terminated.
02
Drugs
everolimusdocetaxel
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ISRCTN73814534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN73814534.